[
  {
    "ts": "2026-02-23T10:30:00+00:00",
    "headline": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
    "summary": "Viking stock has plenty of room to run.",
    "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9dabe636-10b2-3921-929f-f0971dee2050",
      "content": {
        "id": "9dabe636-10b2-3921-929f-f0971dee2050",
        "contentType": "STORY",
        "title": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
        "description": "",
        "summary": "Viking stock has plenty of room to run.",
        "pubDate": "2026-02-23T10:30:00Z",
        "displayTime": "2026-02-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96",
          "originalWidth": 1400,
          "originalHeight": 923,
          "caption": "A researcher works at a laptop in a lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ms0ndEUmtXrFkkoECWj0w--~B/aD05MjM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 1400,
              "height": 923,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6DyizSm4MwCeb5llJR76Lg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-viking-therapeutics-stock-103000062.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:11:20+00:00",
    "headline": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‚Äåwas less effective than Eli Lilly's tirzepatide ‚Äåin a head-to-head trial, a setback in the race ‚Äãfor dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‚Äåfailed to meet ‚Å†that goal, Novo said in a statement.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‚Äåwas less effective than Eli Lilly's tirzepatide ‚Äåin a head-to-head trial, a setback in the race ‚Äãfor dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‚Äåfailed to meet ‚Å†that goal, Novo said in a statement.",
        "pubDate": "2026-02-23T10:11:20Z",
        "displayTime": "2026-02-23T10:11:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:50+00:00",
    "headline": "Novo Nordisk Weight-Loss Drug Less Effective Than Eli Lilly's, Trial Data Shows",
    "summary": "Novo Nordisk (NVO) US-listed shares fell early Monday after the latest trial results of the Danish p",
    "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "a7adad91-791a-3260-81a9-d2c8ff1fd755",
      "content": {
        "id": "a7adad91-791a-3260-81a9-d2c8ff1fd755",
        "contentType": "STORY",
        "title": "Novo Nordisk Weight-Loss Drug Less Effective Than Eli Lilly's, Trial Data Shows",
        "description": "",
        "summary": "Novo Nordisk (NVO) US-listed shares fell early Monday after the latest trial results of the Danish p",
        "pubDate": "2026-02-23T11:36:50Z",
        "displayTime": "2026-02-23T11:36:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "novonordisk - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eliLOTQZlBN.EI2msY8t5Q--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wm42B1.q1CBU9m2gxaHtkw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:37+00:00",
    "headline": "Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Novo Nordisk, Strategy to Decline",
    "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly lower hours before Mo",
    "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9fedea89-ba6c-3d18-bdc6-5b18e61d4744",
      "content": {
        "id": "9fedea89-ba6c-3d18-bdc6-5b18e61d4744",
        "contentType": "STORY",
        "title": "Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Novo Nordisk, Strategy to Decline",
        "description": "",
        "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly lower hours before Mo",
        "pubDate": "2026-02-23T11:36:37Z",
        "displayTime": "2026-02-23T11:36:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AM"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:07:00+00:00",
    "headline": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial",
    "summary": "Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly‚Äôs Zepbound in a head-to-head clinical trial.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
      "content": {
        "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial",
        "description": "",
        "summary": "Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly‚Äôs Zepbound in a head-to-head clinical trial.",
        "pubDate": "2026-02-23T11:07:00Z",
        "displayTime": "2026-02-23T11:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/882d8a85-7d67-34a5-9359-3e21c423286a/novo-nordisk-shares-plunge.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MyL48X4s4gpQWSdt3IrYQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmXDncVkC6u9q6z0TItpZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:58:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More",
    "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More",
        "description": "",
        "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
        "pubDate": "2026-02-23T10:58:00Z",
        "displayTime": "2026-02-23T10:58:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:56:49+00:00",
    "headline": "Podcast: Which pharma and medtech companies came out on top in 2025 revenues?",
    "summary": "The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.",
    "url": "https://www.pharmaceutical-technology.com/features/podcast-which-pharma-and-medtech-companies-came-out-on-top-in-2025-revenues/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "4c21b03b-ac35-3ab5-9dac-67690432c5c0",
      "content": {
        "id": "4c21b03b-ac35-3ab5-9dac-67690432c5c0",
        "contentType": "STORY",
        "title": "Podcast: Which pharma and medtech companies came out on top in 2025 revenues?",
        "description": "",
        "summary": "The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.",
        "pubDate": "2026-02-23T10:56:49Z",
        "displayTime": "2026-02-23T10:56:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e",
          "originalWidth": 1000,
          "originalHeight": 377,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QpPJwBSei73InI9Ki9UVfg--~B/aD0zNzc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e.cf.webp",
              "width": 1000,
              "height": 377,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/34PHKYhhEBdL8cBWzz97_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/features/podcast-which-pharma-and-medtech-companies-came-out-on-top-in-2025-revenues/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/podcast-pharma-medtech-companies-came-105649000.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "EW"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:06:24+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
    "summary": "üîé American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
        "description": "",
        "summary": "üîé American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
        "pubDate": "2026-02-23T10:06:24Z",
        "displayTime": "2026-02-23T10:06:24Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "FBIN"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "UAL"
            },
            {
              "symbol": "D"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:59:38+00:00",
    "headline": "Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound",
    "summary": "Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
      "content": {
        "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
        "contentType": "STORY",
        "title": "Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound",
        "description": "",
        "summary": "Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.",
        "pubDate": "2026-02-23T12:59:38Z",
        "displayTime": "2026-02-23T12:59:38Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/768f33a0-eb6d-3261-823c-4bb7c71825e8/novo-nordisk-dives-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ROtisKKZCPH047T1qbT2JQ--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZHoeLqHyXHi9aWRxqpbIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:39:06+00:00",
    "headline": "Novo Nordisk flags board members for re-election amid restructuring efforts",
    "summary": "Three new board and shareholder-elected members could join Novo‚Äôs council, which largely consists of recent appointees following a restructure in October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/novo-nordisk-board-shakeup-election-recommendations/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "2574fae0-1781-3486-bc4a-4e85119277e7",
      "content": {
        "id": "2574fae0-1781-3486-bc4a-4e85119277e7",
        "contentType": "STORY",
        "title": "Novo Nordisk flags board members for re-election amid restructuring efforts",
        "description": "",
        "summary": "Three new board and shareholder-elected members could join Novo‚Äôs council, which largely consists of recent appointees following a restructure in October 2025.",
        "pubDate": "2026-02-23T12:39:06Z",
        "displayTime": "2026-02-23T12:39:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "Shareholders will determine the composition of Novo Nordisk's board in an Annual General Meeting on the 26 March. Credit: Below the Sky/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySMzM4tODIOV7y_P0R3O7Q--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DMI7l1Dr.8PjmJkLBHD2YQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/novo-nordisk-board-shakeup-election-recommendations/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-flags-board-members-123906245.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "TAK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:38:00+00:00",
    "headline": "1 Reason I'm Seriously Considering Novo Nordisk as a Buy‚Äëand‚ÄëNever‚ÄëSell Obesity Stock",
    "summary": "Novo Nordisk investors get a second bite at the Ozempic apple.",
    "url": "https://www.fool.com/investing/2026/02/23/1-reason-im-seriously-considering-novo-nordisk/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "22c9983e-1e59-377d-86dc-119adf0e52eb",
      "content": {
        "id": "22c9983e-1e59-377d-86dc-119adf0e52eb",
        "contentType": "STORY",
        "title": "1 Reason I'm Seriously Considering Novo Nordisk as a Buy‚Äëand‚ÄëNever‚ÄëSell Obesity Stock",
        "description": "",
        "summary": "Novo Nordisk investors get a second bite at the Ozempic apple.",
        "pubDate": "2026-02-23T12:38:00Z",
        "displayTime": "2026-02-23T12:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A person using a GLP-1 injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vkqbtsuiusy6b2MrKdaKlw--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kBRRw6b9b3ZaNUMosBwTXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/1-reason-im-seriously-considering-novo-nordisk/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-im-seriously-considering-123800435.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:35:16+00:00",
    "headline": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
    "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
    "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
      "content": {
        "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
        "contentType": "STORY",
        "title": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
        "description": "",
        "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
        "pubDate": "2026-02-23T12:35:16Z",
        "displayTime": "2026-02-23T12:35:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "wall street stock market flag new york trading equity - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QVMgErJdOR7IkzCjRHm3pQ--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dimQxOClk1isv1IKNf9JtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:41:55+00:00",
    "headline": "Novo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk's next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, the Danish drugmaker said on Monday, in a setback to its ‚Äåefforts to dominate the weight-loss market. Novo Nordisk is fighting to regain first-mover advantage in the obesity ‚Äåtreatment market, where demand for drugs with higher efficacy has surged.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk's next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, the Danish drugmaker said on Monday, in a setback to its ‚Äåefforts to dominate the weight-loss market. Novo Nordisk is fighting to regain first-mover advantage in the obesity ‚Äåtreatment market, where demand for drugs with higher efficacy has surged.",
        "pubDate": "2026-02-23T11:41:55Z",
        "displayTime": "2026-02-23T11:41:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:32:02+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
    "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
        "description": "",
        "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
        "pubDate": "2026-02-23T11:32:02Z",
        "displayTime": "2026-02-23T11:32:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "UAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:45:58+00:00",
    "headline": "Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin",
    "summary": "Novo Nordisk stock plunged Monday after the drugmaker said its obesity shot, CagriSema, proved less effective than Lilly's tirzepatide.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
      "content": {
        "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
        "contentType": "STORY",
        "title": "Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin",
        "description": "",
        "summary": "Novo Nordisk stock plunged Monday after the drugmaker said its obesity shot, CagriSema, proved less effective than Lilly's tirzepatide.",
        "pubDate": "2026-02-23T14:45:58Z",
        "displayTime": "2026-02-23T14:45:58Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/768f33a0-eb6d-3261-823c-4bb7c71825e8/novo-nordisk-dives-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ROtisKKZCPH047T1qbT2JQ--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZHoeLqHyXHi9aWRxqpbIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:41:07+00:00",
    "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
    "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
        "description": "",
        "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
        "pubDate": "2026-02-23T14:41:07Z",
        "displayTime": "2026-02-23T14:41:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-novo.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:30:58+00:00",
    "headline": "Instant View: Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say",
    "summary": "Feb 23 () - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim its early lead in the booming ‚Äåobesity drug market. Below are some reactions from analysts.",
    "url": "https://finance.yahoo.com/news/novos-cagrisema-setback-may-shift-142956039.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "f0d1e90e-1c2e-3c09-b509-d2e18f45d60b",
      "content": {
        "id": "f0d1e90e-1c2e-3c09-b509-d2e18f45d60b",
        "contentType": "STORY",
        "title": "Instant View: Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say",
        "description": "",
        "summary": "Feb 23 () - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim its early lead in the booming ‚Äåobesity drug market. Below are some reactions from analysts.",
        "pubDate": "2026-02-23T14:30:58Z",
        "displayTime": "2026-02-23T14:30:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/4682edd01f225626d868e144ad2fba23",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/coUXq4i09F1MkVwResIldQ--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4682edd01f225626d868e144ad2fba23.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IFvRfL5jPUjXJcPrydAOJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4682edd01f225626d868e144ad2fba23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-cagrisema-setback-may-shift-142956039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-cagrisema-setback-may-shift-142956039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:11:08+00:00",
    "headline": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
    "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
    "url": "https://uk.finance.yahoo.com/news/weight-loss-drug-trial-results-141108781.html",
    "source": "The Telegraph",
    "provider": "yfinance",
    "raw": {
      "id": "518585eb-8938-388e-93d1-42f16794bdc5",
      "content": {
        "id": "518585eb-8938-388e-93d1-42f16794bdc5",
        "contentType": "STORY",
        "title": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
        "description": "",
        "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
        "pubDate": "2026-02-23T14:11:08Z",
        "displayTime": "2026-02-23T14:11:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_telegraph_818/2c79a69293997315057919a9dce6d429",
          "originalWidth": 2500,
          "originalHeight": 1563,
          "caption": "A pharmacist displays boxes of Ozempic",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vMCwfGLoO2UyX6d7ZKFeaw--~B/aD0xNTYzO3c9MjUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/the_telegraph_818/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 2500,
              "height": 1563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yYEKcmkY3MYuWPwtvtWbZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_telegraph_818/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Telegraph",
          "url": "http://www.telegraph.co.uk/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/weight-loss-drug-trial-results-141108781.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/weight-loss-drug-trial-results-141108781.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:03:58+00:00",
    "headline": "Lilly to launch multi-dose weight-loss drug device in US",
    "summary": "Feb 23 () - Eli Lilly said on Monday it received the U. Food and ‚ÄåDrug Administration's approval to launch a ‚Äåfour-dose KwikPen for its weight-loss drug Zepbound, delivering a ‚Äãfull month of the treatment in a single device.",
    "url": "https://finance.yahoo.com/news/lilly-launch-multi-dose-weight-140358508.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "4be0cadf-d29a-3a57-a149-36127e97eccd",
      "content": {
        "id": "4be0cadf-d29a-3a57-a149-36127e97eccd",
        "contentType": "STORY",
        "title": "Lilly to launch multi-dose weight-loss drug device in US",
        "description": "",
        "summary": "Feb 23 () - Eli Lilly said on Monday it received the U. Food and ‚ÄåDrug Administration's approval to launch a ‚Äåfour-dose KwikPen for its weight-loss drug Zepbound, delivering a ‚Äãfull month of the treatment in a single device.",
        "pubDate": "2026-02-23T14:03:58Z",
        "displayTime": "2026-02-23T14:03:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/662ae5af29f9ed4e31924546092975fd",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rbBbJ4XtXhyrRBspR5VgXw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/662ae5af29f9ed4e31924546092975fd.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NvWObtXyGjKJMhRxVDVdKg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/662ae5af29f9ed4e31924546092975fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-launch-multi-dose-weight-140358508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-launch-multi-dose-weight-140358508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:00:00+00:00",
    "headline": "Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound¬Æ (tirzepatide) to include the four-dose single-patient use KwikPen¬Æ that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for se",
    "url": "https://finance.yahoo.com/news/zepbound-tirzepatide-most-prescribed-weight-140000762.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "291382bf-f293-3060-a091-2251efa87cca",
      "content": {
        "id": "291382bf-f293-3060-a091-2251efa87cca",
        "contentType": "STORY",
        "title": "Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound¬Æ (tirzepatide) to include the four-dose single-patient use KwikPen¬Æ that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for se",
        "pubDate": "2026-02-23T14:00:00Z",
        "displayTime": "2026-02-23T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zepbound-tirzepatide-most-prescribed-weight-140000762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zepbound-tirzepatide-most-prescribed-weight-140000762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:41:13+00:00",
    "headline": "Novo Nordisk's CagriSema falls short against Eli Lilly's in trial",
    "summary": "<body><p>STORY: In a head-to-head trial, Novo Nordisk said its next-generation obesity drug CagriSema was less effective than Eli Lilly's&nbsp;tirzepatide.</p><p>It's a setback for the firm in the race for dominance in the weight-loss drug market.</p><p>The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight.</p><p>But Novo Nordisk said in a statement that it failed to meet that goal.</p><p>Its share price fell as much as&nbsp; 11% by mid-morning trade on Monday.</p><p>The results mean Novo's next-generation treatment delivered less weight loss than Eli Lilly's drug, which is already on the market under the brand name Zepbound and Mounjaro.</p><p>Novo Nordisk said additional trials are exploring the full weight loss potential of CagriSema.</p><p>And include&nbsp;higher-dose combinations.</p><p>Eli Lilly shares rose 4% in U.S. premarket trading.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisks-cagrisema-falls-short-134113322.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "c11983dd-0c8f-3e12-947d-e3b7e0c6939b",
      "content": {
        "id": "c11983dd-0c8f-3e12-947d-e3b7e0c6939b",
        "contentType": "VIDEO",
        "title": "Novo Nordisk's CagriSema falls short against Eli Lilly's in trial",
        "description": "<title><body><p>STORY: In a head-to-head trial, Novo Nordisk said its next-generation obesity drug CagriSema was less effective than Eli Lilly's¬†tirzepatide.</p><p>It's a setback for the firm in the race for dominance in the weight-loss drug market.</p><p>The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight.</p><p>But Novo Nordisk said in a statement that it failed to meet that goal.</p><p>Its share price fell as much as¬† 11% by mid-morning trade on Monday.</p><p>The results mean Novo's next-generation treatment delivered less weight loss than Eli Lilly's drug, which is already on the market under the brand name Zepbound and Mounjaro.</p><p>Novo Nordisk said additional trials are exploring the full weight loss potential of CagriSema.</p><p>And include¬†higher-dose combinations.</p><p>Eli Lilly shares rose 4% in U.S. premarket trading.</p></body></title>",
        "summary": "<body><p>STORY: In a head-to-head trial, Novo Nordisk said its next-generation obesity drug CagriSema was less effective than Eli Lilly's&nbsp;tirzepatide.</p><p>It's a setback for the firm in the race for dominance in the weight-loss drug market.</p><p>The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight.</p><p>But Novo Nordisk said in a statement that it failed to meet that goal.</p><p>Its share price fell as much as&nbsp; 11% by mid-morning trade on Monday.</p><p>The results mean Novo's next-generation treatment delivered less weight loss than Eli Lilly's drug, which is already on the market under the brand name Zepbound and Mounjaro.</p><p>Novo Nordisk said additional trials are exploring the full weight loss potential of CagriSema.</p><p>And include&nbsp;higher-dose combinations.</p><p>Eli Lilly shares rose 4% in U.S. premarket trading.</p></body>",
        "pubDate": "2026-02-23T13:41:13Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/AfJFYDegnRSrrPvEkltUTA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2b6adc23-eabc-4951-bccf-cd1c18f23102/main/1280x720/27s530ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aoqd2xfppRLjjKTjgnu9.g--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2b6adc23-eabc-4951-bccf-cd1c18f23102/main/1280x720/27s530ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_jHMgv2iJOYLOR0CAU7Zhg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2b6adc23-eabc-4951-bccf-cd1c18f23102/main/1280x720/27s530ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisks-cagrisema-falls-short-134113322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisks-cagrisema-falls-short-134113322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:19:45+00:00",
    "headline": "Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly",
    "summary": "COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk's next-generation obesity drug CagriSema underperformed rival Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a setback in its fight to ‚Äåregain leadership of the weight-loss market. Few analysts had predicted CagriSema would be found to be less effective than Lilly's drug that ‚Äåsells as Zepbound in the U.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk's next-generation obesity drug CagriSema underperformed rival Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a setback in its fight to ‚Äåregain leadership of the weight-loss market. Few analysts had predicted CagriSema would be found to be less effective than Lilly's drug that ‚Äåsells as Zepbound in the U.",
        "pubDate": "2026-02-23T13:19:45Z",
        "displayTime": "2026-02-23T13:19:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:09:00+00:00",
    "headline": "Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value",
    "summary": "Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087772/novo-nordisk-s-next-obesity-drug-falls-short-of-lilly-rival-wiping-billions-off-its-market-value-1087772.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "a2b9eb86-65a4-3b2c-b64a-a5eb2a25756c",
      "content": {
        "id": "a2b9eb86-65a4-3b2c-b64a-a5eb2a25756c",
        "contentType": "STORY",
        "title": "Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value",
        "description": "",
        "summary": "Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it...",
        "pubDate": "2026-02-23T13:09:00Z",
        "displayTime": "2026-02-23T13:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/ab43de6574e9ab54523a12fea0e62e4f",
          "originalWidth": 960,
          "originalHeight": 720,
          "caption": "Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2MGsktLslXmUr01bDG8rlQ--~B/aD03MjA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/ab43de6574e9ab54523a12fea0e62e4f.cf.webp",
              "width": 960,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_hiRFqZq8DZPLN0cuZV9dA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/ab43de6574e9ab54523a12fea0e62e4f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087772/novo-nordisk-s-next-obesity-drug-falls-short-of-lilly-rival-wiping-billions-off-its-market-value-1087772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-next-obesity-drug-130900424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:06:00+00:00",
    "headline": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound",
    "summary": "The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
      "content": {
        "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound",
        "description": "",
        "summary": "The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.",
        "pubDate": "2026-02-23T13:06:00Z",
        "displayTime": "2026-02-23T13:06:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/882d8a85-7d67-34a5-9359-3e21c423286a/novo-nordisk-shares-plunge.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MyL48X4s4gpQWSdt3IrYQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmXDncVkC6u9q6z0TItpZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:17:00+00:00",
    "headline": "Novo Nordisk Stock Plunges and Eli Lilly Jumps. It‚Äôs All Down to This Weight-Loss Drug Trial.",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Plunges and Eli Lilly Jumps. It‚Äôs All Down to This Weight-Loss Drug Trial.",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T12:17:00Z",
        "displayTime": "2026-02-23T12:17:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/novo-nordisk-stock-plunges.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:39:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Arcellx, Paramount, Domino‚Äôs Pizza, Nvidia, and More",
    "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Arcellx, Paramount, Domino‚Äôs Pizza, Nvidia, and More",
        "description": "",
        "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
        "pubDate": "2026-02-23T11:39:00Z",
        "displayTime": "2026-02-23T11:39:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:36:00+00:00",
    "headline": "Why Novo Nordisk Stock Is Pluging‚Äîand Why It‚Äôs Good News for Lilly",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Is Pluging‚Äîand Why It‚Äôs Good News for Lilly",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T14:36:00Z",
        "displayTime": "2026-02-23T14:36:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/why-novo-nordisk-stock-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:11:08+00:00",
    "headline": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
    "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
    "url": "https://www.telegraph.co.uk/business/2026/02/23/almost-150bn-wiped-off-ozempic-maker/",
    "source": "The Telegraph",
    "provider": "yfinance",
    "raw": {
      "id": "b5219425-d18d-37a8-abdc-89820545c171",
      "content": {
        "id": "b5219425-d18d-37a8-abdc-89820545c171",
        "contentType": "STORY",
        "title": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
        "description": "",
        "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
        "pubDate": "2026-02-23T14:11:08Z",
        "displayTime": "2026-02-23T14:11:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_telegraph_258/2c79a69293997315057919a9dce6d429",
          "originalWidth": 2500,
          "originalHeight": 1563,
          "caption": "A pharmacist displays boxes of Ozempic",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ALin_3Im9r_Pv45XONE3YA--~B/aD0xNTYzO3c9MjUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/the_telegraph_258/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 2500,
              "height": 1563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rzFrufKBs9U2YaWNUs5_fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_telegraph_258/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Telegraph",
          "url": "http://www.telegraph.co.uk/"
        },
        "canonicalUrl": {
          "url": "https://www.telegraph.co.uk/business/2026/02/23/almost-150bn-wiped-off-ozempic-maker/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/weight-loss-drug-trial-results-141108858.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:07:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, Domino‚Äôs, United Airlines, International Paper, Strategy, and More",
    "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, Domino‚Äôs, United Airlines, International Paper, Strategy, and More",
        "description": "",
        "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
        "pubDate": "2026-02-23T14:07:00Z",
        "displayTime": "2026-02-23T14:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "IP"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:15:21+00:00",
    "headline": "Trump puts pressure on Netflix board, Domino's stock rises on Q4",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks several of the day's top trending stock tickers, including Variety reporting that Paramount Skydance (PSKY) plans to up its bid for Warner Bros. Discovery (WBD) while President Trump puts pressure on Netflix (NFLX) to fire his former US ambassador and national security advisor, Susan Rice, from the streaming giant's board. Novo Nordisk (NVO) stock is falling on Monday after its weight-loss drug underperformed compared to Eli Lilly's own GLP-1 in a clinical trial. And, Domino's Pizza (DPZ) shares getting a lift higher when the chain topped fourth quarter revenue estimates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
    "url": "https://finance.yahoo.com/video/trump-puts-pressure-netflix-board-161521046.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "d086c06e-ced2-3654-86cc-6e054503a1e3",
      "content": {
        "id": "d086c06e-ced2-3654-86cc-6e054503a1e3",
        "contentType": "VIDEO",
        "title": "Trump puts pressure on Netflix board, Domino's stock rises on Q4",
        "description": "<p>Yahoo Finance Senior Reporter <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/brooke-dipalma/\">Brooke DiPalma</a> tracks several of the day's top trending stock tickers, including <a data-i13n=\"cpos:2;pos:1\" href=\"https://variety.com/2026/film/news/paramount-warner-bros-discovery-higher-bid-will-netflix-walk-away-1236670140/\">Variety reporting</a> that Paramount Skydance (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/PSKY\">PSKY</a>) plans to up its bid for Warner Bros. Discovery (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/WBD\">WBD</a>) while President Trump puts pressure on Netflix (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/NFLX\">NFLX</a>) to fire his former US ambassador and national security advisor, Susan Rice, from the streaming giant's board.</p>\n<p>Novo Nordisk (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) stock is falling on Monday after its weight-loss drug underperformed compared to Eli Lilly's own GLP-1 in a clinical trial.</p>\n<p>And, Domino's Pizza (<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/DPZ\">DPZ</a>) shares getting a lift higher when the chain topped fourth quarter revenue estimates.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more¬†<a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks several of the day's top trending stock tickers, including Variety reporting that Paramount Skydance (PSKY) plans to up its bid for Warner Bros. Discovery (WBD) while President Trump puts pressure on Netflix (NFLX) to fire his former US ambassador and national security advisor, Susan Rice, from the streaming giant's board. Novo Nordisk (NVO) stock is falling on Monday after its weight-loss drug underperformed compared to Eli Lilly's own GLP-1 in a clinical trial. And, Domino's Pizza (DPZ) shares getting a lift higher when the chain topped fourth quarter revenue estimates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
        "pubDate": "2026-02-23T16:15:21Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/a9b5b330-10d2-11f1-bf6e-0b64edec3636",
          "originalWidth": 8179,
          "originalHeight": 4605,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zo4vQaBSkj0SDyOUNBCgRA--~B/aD00NjA1O3c9ODE3OTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/a9b5b330-10d2-11f1-bf6e-0b64edec3636.cf.webp",
              "width": 8179,
              "height": 4605,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lf8p29qjfM3LKYWZCn6Q6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/a9b5b330-10d2-11f1-bf6e-0b64edec3636.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/trump-puts-pressure-netflix-board-161521046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/trump-puts-pressure-netflix-board-161521046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "WBD"
            },
            {
              "symbol": "NFLX"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:55:09+00:00",
    "headline": "Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out",
    "summary": "Feb 23 () - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‚Äågains brought by its blockbuster weight-loss drug Wegovy, ‚Äåafter the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's ‚Äãrival. Novo, which in 2024 was worth more than $650 billion, has since shed around $475 billion, with the shares back at levels last seen before Wegovy transformed it into Europe's most ‚Äåvaluable drugmaker.",
    "url": "https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e6200641-1661-302c-af58-986a30e9501e",
      "content": {
        "id": "e6200641-1661-302c-af58-986a30e9501e",
        "contentType": "STORY",
        "title": "Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out",
        "description": "",
        "summary": "Feb 23 () - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‚Äågains brought by its blockbuster weight-loss drug Wegovy, ‚Äåafter the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's ‚Äãrival. Novo, which in 2024 was worth more than $650 billion, has since shed around $475 billion, with the shares back at levels last seen before Wegovy transformed it into Europe's most ‚Äåvaluable drugmaker.",
        "pubDate": "2026-02-23T16:55:09Z",
        "displayTime": "2026-02-23T16:55:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/a075817c163ee72586baea1e41f68cec",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "Novo Nordisk logo and decreasing stock graph are seen in this illustration taken August 5, 2025. REUTERS/Dado Ruvic/Illustration",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ariLHLDvDF6uTtsxpkT.aA--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a075817c163ee72586baea1e41f68cec.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cIq.nZj9rvpT7htGzt80vg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a075817c163ee72586baea1e41f68cec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:16:00+00:00",
    "headline": "Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion",
    "summary": "All three major US stock indexes were down in late-morning trading Monday, as investors weigh the co",
    "url": "https://finance.yahoo.com/news/top-midday-stories-novo-obesity-161600151.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "66575aac-2f77-37e7-b76f-213bb003012b",
      "content": {
        "id": "66575aac-2f77-37e7-b76f-213bb003012b",
        "contentType": "STORY",
        "title": "Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion",
        "description": "",
        "summary": "All three major US stock indexes were down in late-morning trading Monday, as investors weigh the co",
        "pubDate": "2026-02-23T16:16:00Z",
        "displayTime": "2026-02-23T16:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-novo-obesity-161600151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-novo-obesity-161600151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:15:40+00:00",
    "headline": "Why Eli Lilly Stock Just Popped",
    "summary": "Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).",
    "url": "https://www.fool.com/investing/2026/02/23/why-eli-lilly-stock-just-popped/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c737d9bc-83fd-3ed4-abbe-b8200992682b",
      "content": {
        "id": "c737d9bc-83fd-3ed4-abbe-b8200992682b",
        "contentType": "STORY",
        "title": "Why Eli Lilly Stock Just Popped",
        "description": "",
        "summary": "Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).",
        "pubDate": "2026-02-23T16:15:40Z",
        "displayTime": "2026-02-23T16:15:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/592d8d4e76e03021201e00455b5ee5fb",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Woman injecting self in arm with a GLP-1 injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iVABqu0W2EYyD2OTb9hsTA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/592d8d4e76e03021201e00455b5ee5fb.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pzab1GKpnfAGf2Mo2eEb6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/592d8d4e76e03021201e00455b5ee5fb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/why-eli-lilly-stock-just-popped/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-stock-just-161540738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:10:51+00:00",
    "headline": "Novo Nordisk Sinks, Lilly Surges After Obesity Drug Trial Shock",
    "summary": "Novo Nordisk Stock Slides After CagriSema Disappoints in Late-Stage Study",
    "url": "https://finance.yahoo.com/news/novo-nordisk-sinks-lilly-surges-161051308.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "9f4f248f-36a0-3caa-bdf2-928bc7ddcb61",
      "content": {
        "id": "9f4f248f-36a0-3caa-bdf2-928bc7ddcb61",
        "contentType": "STORY",
        "title": "Novo Nordisk Sinks, Lilly Surges After Obesity Drug Trial Shock",
        "description": "",
        "summary": "Novo Nordisk Stock Slides After CagriSema Disappoints in Late-Stage Study",
        "pubDate": "2026-02-23T16:10:51Z",
        "displayTime": "2026-02-23T16:10:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sinks-lilly-surges-161051308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sinks-lilly-surges-161051308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:51:24+00:00",
    "headline": "Why Novo Nordisk Stock Just Crashed",
    "summary": "GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.",
    "url": "https://www.fool.com/investing/2026/02/23/why-novo-nordisk-stock-just-crashed/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6491744c-3000-3312-a7ac-0609931d2334",
      "content": {
        "id": "6491744c-3000-3312-a7ac-0609931d2334",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Just Crashed",
        "description": "",
        "summary": "GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.",
        "pubDate": "2026-02-23T15:51:24Z",
        "displayTime": "2026-02-23T15:51:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/63da39fd621e94abb6624ad96f58663d",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "GLP-1 Semaglutide injector pens in a box.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YeqceUsyoZQr9sNviqDXCw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/63da39fd621e94abb6624ad96f58663d.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hzxTv57Pdx7MnqHTcbL0jA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/63da39fd621e94abb6624ad96f58663d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/why-novo-nordisk-stock-just-crashed/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-novo-nordisk-stock-just-155124895.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:50:00+00:00",
    "headline": "Eli Lilly: The Weight‚ÄëLoss and Diabetes Powerhouse I'd Hold Through Any Market Crash",
    "summary": "The stock looks unstoppable.",
    "url": "https://www.fool.com/investing/2026/02/23/eli-lilly-the-weight-loss-powerhouse-id-hold/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "42bccf66-7075-3ef6-aef8-f1029b68cc18",
      "content": {
        "id": "42bccf66-7075-3ef6-aef8-f1029b68cc18",
        "contentType": "STORY",
        "title": "Eli Lilly: The Weight‚ÄëLoss and Diabetes Powerhouse I'd Hold Through Any Market Crash",
        "description": "",
        "summary": "The stock looks unstoppable.",
        "pubDate": "2026-02-23T15:50:00Z",
        "displayTime": "2026-02-23T15:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/25b0e3db14b43d53726443021cae478a",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Patient self-administering an injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mvcQ1_uFMeInm9mut.9ZhQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/25b0e3db14b43d53726443021cae478a.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JAUNS.CnUhB0uaLH.S1Vqw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/25b0e3db14b43d53726443021cae478a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/eli-lilly-the-weight-loss-powerhouse-id-hold/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-weight-loss-diabetes-155000029.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:47:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino‚Äôs, Packaging Corp., and More",
    "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino‚Äôs, Packaging Corp., and More",
        "description": "",
        "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
        "pubDate": "2026-02-23T15:47:00Z",
        "displayTime": "2026-02-23T15:47:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "STRC"
            },
            {
              "symbol": "STRD"
            },
            {
              "symbol": "STRF"
            },
            {
              "symbol": "STRK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PKG"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "JBLU"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "SW"
            },
            {
              "symbol": "IP"
            },
            {
              "symbol": "ALK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:18:00+00:00",
    "headline": "Why Novo Nordisk Stock Is Plunging‚Äîand Why It‚Äôs Good News for Lilly",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Is Plunging‚Äîand Why It‚Äôs Good News for Lilly",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T15:18:00Z",
        "displayTime": "2026-02-23T15:18:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/why-novo-nordisk-stock-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:46:00+00:00",
    "headline": "Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace",
    "summary": "MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace hit 5-year highs as double-digit 2026 earnings growth fuels a new \"Magnificent\" list.",
    "url": "https://finance.yahoo.com/news/zacks-market-edge-highlights-mastec-144600938.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "001fed99-af3f-38d8-bf34-2e37eeef375a",
      "content": {
        "id": "001fed99-af3f-38d8-bf34-2e37eeef375a",
        "contentType": "STORY",
        "title": "Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace",
        "description": "",
        "summary": "MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace hit 5-year highs as double-digit 2026 earnings growth fuels a new \"Magnificent\" list.",
        "pubDate": "2026-02-23T14:46:00Z",
        "displayTime": "2026-02-23T14:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3d76cb528670a51f2c5ec1e11cfb6cdb",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BmCFfbDuZLdBtIMkVFr5BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d76cb528670a51f2c5ec1e11cfb6cdb.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5qb0jADCn4EWNS9hfwqFrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d76cb528670a51f2c5ec1e11cfb6cdb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-market-edge-highlights-mastec-144600938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-market-edge-highlights-mastec-144600938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BRK-B"
            },
            {
              "symbol": "MTZ"
            },
            {
              "symbol": "CAT"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "HWM"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "BAC"
            },
            {
              "symbol": "UNP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:41:07+00:00",
    "headline": "Stocks to Watch Monday: Merck, Novo Nordisk, Eli Lilly, Gilead",
    "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Merck, Novo Nordisk, Eli Lilly, Gilead",
        "description": "",
        "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
        "pubDate": "2026-02-23T14:41:07Z",
        "displayTime": "2026-02-23T14:41:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T17:06:00+00:00",
    "headline": "Eli Lilly‚Äôs Zepbound Gets FDA OK for Multi-Dose Pen",
    "summary": "The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device.",
    "url": "https://www.wsj.com/health/pharma/eli-lillys-zepbound-gets-fda-ok-for-multi-dose-pen-626350cb?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "66c62213-5d3a-3c7c-8ff2-b5f1eba0b8c1",
      "content": {
        "id": "66c62213-5d3a-3c7c-8ff2-b5f1eba0b8c1",
        "contentType": "STORY",
        "title": "Eli Lilly‚Äôs Zepbound Gets FDA OK for Multi-Dose Pen",
        "description": "",
        "summary": "The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device.",
        "pubDate": "2026-02-23T17:06:00Z",
        "displayTime": "2026-02-23T17:06:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/66c62213-5d3a-3c7c-8ff2-b5f1eba0b8c1/eli-lilly%E2%80%99s-zepbound-gets-fda.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/545e9908188511493cde744a7cfc6dea",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3RBFIut9s0AVFTpDh7KNYw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/545e9908188511493cde744a7cfc6dea.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WD4RU0X9pkRz6COe3H4_jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/545e9908188511493cde744a7cfc6dea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lillys-zepbound-gets-fda-ok-for-multi-dose-pen-626350cb?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:08:28+00:00",
    "headline": "Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why",
    "summary": "Novo Nordisk shares plunged Monday after the Ozempic and Wegovy maker's newest drug trial results came in short of expectations.",
    "url": "https://www.investopedia.com/novo-nordisk-stock-tumbles-monday-to-its-lowest-point-in-nearly-5-years-here-is-why-nvo-11911674",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "3c965d13-65f4-39ba-a6a7-14886edb3bb4",
      "content": {
        "id": "3c965d13-65f4-39ba-a6a7-14886edb3bb4",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why",
        "description": "",
        "summary": "Novo Nordisk shares plunged Monday after the Ozempic and Wegovy maker's newest drug trial results came in short of expectations.",
        "pubDate": "2026-02-23T16:08:28Z",
        "displayTime": "2026-02-23T16:08:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/b8cf36402ab30de2eda7d5948a4ac9c3",
          "originalWidth": 5472,
          "originalHeight": 3648,
          "caption": "With Monday's drop, Novo Nordisk shares have lost more than half their value in the last 12 months Kristian Tuxen Ladegaard Berg / NurPhoto / Getty Images",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7qXD4JRYHApvThG9Fy5XYg--~B/aD0zNjQ4O3c9NTQ3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/b8cf36402ab30de2eda7d5948a4ac9c3.cf.webp",
              "width": 5472,
              "height": 3648,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/miLqpDxo48ULjQ93VBzzdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/b8cf36402ab30de2eda7d5948a4ac9c3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/novo-nordisk-stock-tumbles-monday-to-its-lowest-point-in-nearly-5-years-here-is-why-nvo-11911674",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-stock-tumbles-monday-160828296.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:11:53+00:00",
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for Feb. 23, 2026",
    "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-february-23-2026-11911668",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "fe09c3bf-2624-3597-ac4d-a431a8fca2d2",
      "content": {
        "id": "fe09c3bf-2624-3597-ac4d-a431a8fca2d2",
        "contentType": "STORY",
        "title": "5 Things to Know Before the Stock Market Opens",
        "description": "",
        "summary": "News of the day for Feb. 23, 2026",
        "pubDate": "2026-02-23T13:11:53Z",
        "displayTime": "2026-02-23T13:11:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/3dfc990e355c0b55b2f278ee4ecd1ab0",
          "originalWidth": 6720,
          "originalHeight": 4480,
          "caption": "The Nasdaq Composite rose 1.5% last week, snapping a five-week losing streak for the tech-heavy index. Michael Nagle / Bloomberg / Getty Images",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RF1gKejF5NY38czNBByI2g--~B/aD00NDgwO3c9NjcyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/3dfc990e355c0b55b2f278ee4ecd1ab0.cf.webp",
              "width": 6720,
              "height": 4480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jshBzKVDaL.5d6pP8ViUsQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/3dfc990e355c0b55b2f278ee4ecd1ab0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-february-23-2026-11911668",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-things-know-stock-market-131153421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LOW"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BRK.A"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "HD"
            },
            {
              "symbol": "CRM"
            },
            {
              "symbol": "DELL"
            },
            {
              "symbol": "TJX"
            },
            {
              "symbol": "UAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "AAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:22:33+00:00",
    "headline": "Novo‚Äôs next-gen obesity shot fails to match Lilly drug in head-to-head study",
    "summary": "Shares fell by more than 15% on results showing study participants receiving Novo‚Äôs CagriSema¬†lost less weight than those who took Lilly‚Äôs Zepbound.",
    "url": "https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "f72539d4-aea4-3e6a-a8e1-e206d2f15f2d",
      "content": {
        "id": "f72539d4-aea4-3e6a-a8e1-e206d2f15f2d",
        "contentType": "STORY",
        "title": "Novo‚Äôs next-gen obesity shot fails to match Lilly drug in head-to-head study",
        "description": "",
        "summary": "Shares fell by more than 15% on results showing study participants receiving Novo‚Äôs CagriSema¬†lost less weight than those who took Lilly‚Äôs Zepbound.",
        "pubDate": "2026-02-23T12:22:33Z",
        "displayTime": "2026-02-23T12:22:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/5fefbc9736ee581e63978dee9cc9b8cd",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Novo Nordisk research center in Indianapolis, Ind., on March 15, 2023.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lThwcKwb6MD8u_ypPAGhlw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/5fefbc9736ee581e63978dee9cc9b8cd.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4OZN81QRtGmiDIPI63Z5KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/5fefbc9736ee581e63978dee9cc9b8cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-next-gen-obesity-shot-122233658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T19:51:09+00:00",
    "headline": "Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs‚Äôs top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) worked better than Taltz alone in adults who had moderate-to-severe plaque psoriasis and also had obesity or were overweight. Eli Lilly said the results came [‚Ä¶]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-expands-pipeline-195109949.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "38e31e46-e828-36bf-994d-3b275851943a",
      "content": {
        "id": "38e31e46-e828-36bf-994d-3b275851943a",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs‚Äôs top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) worked better than Taltz alone in adults who had moderate-to-severe plaque psoriasis and also had obesity or were overweight. Eli Lilly said the results came [‚Ä¶]",
        "pubDate": "2026-02-23T19:51:09Z",
        "displayTime": "2026-02-23T19:51:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/855f312b5cb94a02c9188db15295e4c9",
          "originalWidth": 640,
          "originalHeight": 360,
          "caption": "Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B0XIzI78wkmKnr46in5uXg--~B/aD0zNjA7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/855f312b5cb94a02c9188db15295e4c9.cf.webp",
              "width": 640,
              "height": 360,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SNi5CAAeBWIIGA3rcstcMg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/855f312b5cb94a02c9188db15295e4c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-expands-pipeline-195109949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-expands-pipeline-195109949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T19:30:00+00:00",
    "headline": "Nasdaq, Dow Jones start the week lower as Trump resets tariffs",
    "summary": "2:30pm: Market movers Domino's Pizza Inc (NYSE:DPZ) shares rose more than 2% after the pizza chain released mixed results for the fourth quarter of 2025, with revenue topping expectations on increased sales. Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087770/nasdaq-and-dow-jones-set-to-start-week-lower-as-trump-resets-tariffs-1087770.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "4e3c0b37-8d13-31d5-afb7-b3aa0ecf5ff9",
      "content": {
        "id": "4e3c0b37-8d13-31d5-afb7-b3aa0ecf5ff9",
        "contentType": "STORY",
        "title": "Nasdaq, Dow Jones start the week lower as Trump resets tariffs",
        "description": "",
        "summary": "2:30pm: Market movers Domino's Pizza Inc (NYSE:DPZ) shares rose more than 2% after the pizza chain released mixed results for the fourth quarter of 2025, with revenue topping expectations on increased sales. Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug...",
        "pubDate": "2026-02-23T19:30:00Z",
        "displayTime": "2026-02-23T19:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/8db0fce3dcb5d65bbaa5d076609f629f",
          "originalWidth": 1079,
          "originalHeight": 720,
          "caption": "Nasdaq, Dow Jones start the week lower as Trump resets tariffs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LInJalPcC3KXRRB.s2eOjQ--~B/aD03MjA7dz0xMDc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/proactive_us_504/8db0fce3dcb5d65bbaa5d076609f629f.cf.webp",
              "width": 1079,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ev9jGK3Z2cc3rA1Z7pMcGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/8db0fce3dcb5d65bbaa5d076609f629f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087770/nasdaq-and-dow-jones-set-to-start-week-lower-as-trump-resets-tariffs-1087770.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nasdaq-dow-jones-set-start-125500793.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "TOM.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T19:10:14+00:00",
    "headline": "Equities, Treasury Yields Fall Intraday as Markets Weigh New Trump Tariffs",
    "summary": "US benchmark equity indexes and Treasury yields fell intraday as investors assessed new tariffs anno",
    "url": "https://finance.yahoo.com/news/equities-treasury-yields-fall-intraday-191014456.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "a23e57d1-134e-333a-a02f-fc626ef2cec9",
      "content": {
        "id": "a23e57d1-134e-333a-a02f-fc626ef2cec9",
        "contentType": "STORY",
        "title": "Equities, Treasury Yields Fall Intraday as Markets Weigh New Trump Tariffs",
        "description": "",
        "summary": "US benchmark equity indexes and Treasury yields fell intraday as investors assessed new tariffs anno",
        "pubDate": "2026-02-23T19:10:14Z",
        "displayTime": "2026-02-23T19:10:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a",
          "originalWidth": 1024,
          "originalHeight": 768,
          "caption": "Stocks_Chart market equity trading wall street - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0eWqzzTTIs4ZCQG0VOzLjA--~B/aD03Njg7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a.cf.webp",
              "width": 1024,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/woUn3cfJYPXMhxA4_4CCeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/equities-treasury-yields-fall-intraday-191014456.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/equities-treasury-yields-fall-intraday-191014456.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:50:31+00:00",
    "headline": "Stocks to Watch Monday: Merck, Netflix, Novo Nordisk, Eli Lilly",
    "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares edged higher 1% on a strong day for health-care stocks.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Merck, Netflix, Novo Nordisk, Eli Lilly",
        "description": "",
        "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares edged higher 1% on a strong day for health-care stocks.",
        "pubDate": "2026-02-23T18:50:31Z",
        "displayTime": "2026-02-23T18:50:31Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/fdd47d79dd303dd8ed75edc6302549ad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fE8MPZmAGd3rI2qE9tOdFg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/fdd47d79dd303dd8ed75edc6302549ad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.05UnUkL1bcbBSdeL6wDDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/fdd47d79dd303dd8ed75edc6302549ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:12:37+00:00",
    "headline": "Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock. The firm said GLP-1 weight loss treatments represent a ‚Äúdurable structural [‚Ä¶]",
    "url": "https://finance.yahoo.com/news/barclays-begins-coverage-eli-lilly-181237134.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f585722a-5fe0-31c6-8853-5f58c857a975",
      "content": {
        "id": "f585722a-5fe0-31c6-8853-5f58c857a975",
        "contentType": "STORY",
        "title": "Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock. The firm said GLP-1 weight loss treatments represent a ‚Äúdurable structural [‚Ä¶]",
        "pubDate": "2026-02-23T18:12:37Z",
        "displayTime": "2026-02-23T18:12:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-begins-coverage-eli-lilly-181237134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-begins-coverage-eli-lilly-181237134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BCS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:10:57+00:00",
    "headline": "Novo Nordisk Trips in the Obesity Race",
    "summary": "Pill trial setback dents Novo‚Äôs obesity comeback hopes.",
    "url": "https://app.moby.co/home/news/news-novo-nordisk-trips-in-the-obesity-race?utm_source=yahoo_finance&utm_medium=rss",
    "source": "Moby",
    "provider": "yfinance",
    "raw": {
      "id": "9127ed0f-eccc-3d9e-86bf-7c76ddf6d958",
      "content": {
        "id": "9127ed0f-eccc-3d9e-86bf-7c76ddf6d958",
        "contentType": "STORY",
        "title": "Novo Nordisk Trips in the Obesity Race",
        "description": "",
        "summary": "Pill trial setback dents Novo‚Äôs obesity comeback hopes.",
        "pubDate": "2026-02-23T18:10:57Z",
        "displayTime": "2026-02-23T18:10:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/moby_896/b5cdc96ea7e5307e77914c71bed26ef2",
          "originalWidth": 1024,
          "originalHeight": 1536,
          "caption": "Novo Nordisk Trips in the Obesity Race",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YARDNWKLtwhC5nxszoaXlA--~B/aD0xNTM2O3c9MTAyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/moby_896/b5cdc96ea7e5307e77914c71bed26ef2.cf.webp",
              "width": 1024,
              "height": 1536,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cXIfPDX7OAVnwrJRylWH3g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/moby_896/b5cdc96ea7e5307e77914c71bed26ef2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Moby",
          "url": "https://moby.co/"
        },
        "canonicalUrl": {
          "url": "https://app.moby.co/home/news/news-novo-nordisk-trips-in-the-obesity-race?utm_source=yahoo_finance&utm_medium=rss",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-trips-obesity-race-181057650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:03:19+00:00",
    "headline": "Why Viking Therapeutics Stock Is Up More Than 9% Today",
    "summary": "A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.",
    "url": "https://www.fool.com/investing/2026/02/23/why-viking-therapeutics-stock-is-up-more-than-9-to/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "0f901aeb-9368-3a31-9cf4-6cd88607784c",
      "content": {
        "id": "0f901aeb-9368-3a31-9cf4-6cd88607784c",
        "contentType": "STORY",
        "title": "Why Viking Therapeutics Stock Is Up More Than 9% Today",
        "description": "",
        "summary": "A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.",
        "pubDate": "2026-02-23T18:03:19Z",
        "displayTime": "2026-02-23T18:03:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/760ca77219b78493ac9fdc8306c8d631",
          "originalWidth": 1400,
          "originalHeight": 906,
          "caption": "A bar chart is rising.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PBnCthC276IRgyIOpiIsYw--~B/aD05MDY7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/760ca77219b78493ac9fdc8306c8d631.cf.webp",
              "width": 1400,
              "height": 906,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PNL1odPbtulJ8e3y3IH3zw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/760ca77219b78493ac9fdc8306c8d631.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/why-viking-therapeutics-stock-is-up-more-than-9-to/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-viking-therapeutics-stock-more-180319724.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:01:22+00:00",
    "headline": "Novo Nordisk Shares Drop 15% After CagriSema Misses Phase 3 Goal",
    "summary": "REDEFINE 4 shows 20.2% weight loss for CagriSema versus 23.6% for Lilly's tirzepatide over 84 weeks.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-shares-drop-15-180122947.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "4ea60e1b-95f3-3f4e-bb82-6a1b41619555",
      "content": {
        "id": "4ea60e1b-95f3-3f4e-bb82-6a1b41619555",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Drop 15% After CagriSema Misses Phase 3 Goal",
        "description": "",
        "summary": "REDEFINE 4 shows 20.2% weight loss for CagriSema versus 23.6% for Lilly's tirzepatide over 84 weeks.",
        "pubDate": "2026-02-23T18:01:22Z",
        "displayTime": "2026-02-23T18:01:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-drop-15-180122947.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-drop-15-180122947.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T17:48:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, CrowdStrike, American Airlines, Strategy, Domino‚Äôs, and More",
    "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, CrowdStrike, American Airlines, Strategy, Domino‚Äôs, and More",
        "description": "",
        "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
        "pubDate": "2026-02-23T17:48:00Z",
        "displayTime": "2026-02-23T17:48:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "STRC"
            },
            {
              "symbol": "STRD"
            },
            {
              "symbol": "STRF"
            },
            {
              "symbol": "STRK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "CRWD"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "IP"
            },
            {
              "symbol": "PKG"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "JBLU"
            },
            {
              "symbol": "ALK"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T17:44:22+00:00",
    "headline": "Novo Next-Generation Obesity Shot Falls Short of Lilly Rival",
    "summary": "Novo Nordisk's next-generation obesity shot delivered less weight loss than&nbsp;Eli Lilly rival blockbuster in yet another blow to the Danish company's attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo's CagriSema in a&nbsp;trial&nbsp;achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly's tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda.",
    "url": "https://finance.yahoo.com/video/novo-next-generation-obesity-shot-174422289.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "78019eb8-2198-3b05-9548-1ae8660d978d",
      "content": {
        "id": "78019eb8-2198-3b05-9548-1ae8660d978d",
        "contentType": "VIDEO",
        "title": "Novo Next-Generation Obesity Shot Falls Short of Lilly Rival",
        "description": "Novo Nordisk's next-generation obesity shot delivered less weight loss than¬†Eli Lilly rival blockbuster in yet another blow to the Danish company's attempts to regain lost ground in the weight-loss market.\nPeople treated with a standard dose of Novo's CagriSema in a¬†trial¬†achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly's tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda.",
        "summary": "Novo Nordisk's next-generation obesity shot delivered less weight loss than&nbsp;Eli Lilly rival blockbuster in yet another blow to the Danish company's attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo's CagriSema in a&nbsp;trial&nbsp;achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly's tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda.",
        "pubDate": "2026-02-23T17:44:22Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/7221f51f66150e949e3dbd378f760ab6",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EM_.uj1avT6hP.j8Dl7PrA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/7221f51f66150e949e3dbd378f760ab6.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5TKkyVrhn1Orw6fsLWHjjA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/7221f51f66150e949e3dbd378f760ab6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-next-generation-obesity-shot-174422289.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-next-generation-obesity-shot-174422289.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:51:26+00:00",
    "headline": "Dow Logs Worst Day in Nearly 5 Weeks Amid Renewed Tariffs Uncertainty; Tech Stocks Fall",
    "summary": "The Dow Jones Industrial Average posted its biggest one-day drop in nearly five weeks on Monday amid",
    "url": "https://finance.yahoo.com/news/dow-logs-worst-day-nearly-215126118.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c5919be7-a169-3431-bf27-51008a8abeca",
      "content": {
        "id": "c5919be7-a169-3431-bf27-51008a8abeca",
        "contentType": "STORY",
        "title": "Dow Logs Worst Day in Nearly 5 Weeks Amid Renewed Tariffs Uncertainty; Tech Stocks Fall",
        "description": "",
        "summary": "The Dow Jones Industrial Average posted its biggest one-day drop in nearly five weeks on Monday amid",
        "pubDate": "2026-02-23T21:51:26Z",
        "displayTime": "2026-02-23T21:51:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/ebc5b64c4dc98d6f607464cb4d50ba3d",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "stock trading floor NYSE market wall street  - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IeAizqJZBy9vwDXxekAvFA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/ebc5b64c4dc98d6f607464cb4d50ba3d.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OyOVBGCbqGk3V7zjfLwvvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/ebc5b64c4dc98d6f607464cb4d50ba3d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/dow-logs-worst-day-nearly-215126118.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dow-logs-worst-day-nearly-215126118.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:40:15+00:00",
    "headline": "Stock Market Today: Dow Sinks As EU Makes Trump Tariff Move; IBM Dives On This AI Threat (Live Coverage)",
    "summary": "Indexes, including the Dow Jones industrials, dived on the stock market today. The EU made a Trump tariff move. Novo stock slid but gold plays shined.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-trump-tariffs-novo-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f65a060d-3459-3bd1-ba64-70ed322cb17d",
      "content": {
        "id": "f65a060d-3459-3bd1-ba64-70ed322cb17d",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Sinks As EU Makes Trump Tariff Move; IBM Dives On This AI Threat (Live Coverage)",
        "description": "",
        "summary": "Indexes, including the Dow Jones industrials, dived on the stock market today. The EU made a Trump tariff move. Novo stock slid but gold plays shined.",
        "pubDate": "2026-02-23T21:40:15Z",
        "displayTime": "2026-02-23T21:40:15Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f65a060d-3459-3bd1-ba64-70ed322cb17d/stock-market-today-dow-sinks.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/da8fe3de95e98df41551b71e3d730b5b",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tu6fhZCxJR58kOHgJIbwqQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/da8fe3de95e98df41551b71e3d730b5b.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jBrIiyeKg2JKCuyzILs2fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/da8fe3de95e98df41551b71e3d730b5b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-trump-tariffs-novo-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBM"
            },
            {
              "symbol": "VZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "AXP"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "V"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "PYPL"
            },
            {
              "symbol": "ZBRA"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "ALB"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "TEAM"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "MCD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:27:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, PayPal, Arcellx, CrowdStrike, KKR, Strategy, and More",
    "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, PayPal, Arcellx, CrowdStrike, KKR, Strategy, and More",
        "description": "",
        "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
        "pubDate": "2026-02-23T21:27:00Z",
        "displayTime": "2026-02-23T21:27:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "STRC"
            },
            {
              "symbol": "STRD"
            },
            {
              "symbol": "STRF"
            },
            {
              "symbol": "STRK"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PYPL"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "CRWD"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:05:42+00:00",
    "headline": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it was as effective as Lilly's tirzepatide in a head-to-head clinical trial.",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-stock-know-210542256.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "ca8d1887-62cd-30c1-9c4a-bc991f27a213",
      "content": {
        "id": "ca8d1887-62cd-30c1-9c4a-bc991f27a213",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
        "description": "",
        "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it was as effective as Lilly's tirzepatide in a head-to-head clinical trial.",
        "pubDate": "2026-02-23T21:05:42Z",
        "displayTime": "2026-02-23T21:05:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "LLY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7jUkGcVljBpqcrgSnimZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fw6rZdJZ6CRFkLxhDmPhew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-stock-know-210542256.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-stock-know-210542256.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:01:29+00:00",
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-210129362.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "3d10cb86-fb30-36bd-b01e-8ad9d4fd8015",
      "content": {
        "id": "3d10cb86-fb30-36bd-b01e-8ad9d4fd8015",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Higher Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
        "pubDate": "2026-02-23T21:01:29Z",
        "displayTime": "2026-02-23T21:01:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-210129362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-210129362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBRX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T20:32:00+00:00",
    "headline": "Why Novo Nordisk Stock Is Plunging‚Äîand Why It‚Äôs Good News for Eli Lilly",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Is Plunging‚Äîand Why It‚Äôs Good News for Eli Lilly",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T20:32:00Z",
        "displayTime": "2026-02-23T20:32:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/why-novo-nordisk-stock-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T23:13:39+00:00",
    "headline": "How The Eli Lilly (LLY) Narrative Is Shifting Around Obesity Leadership And Valuation Risks",
    "summary": "Eli Lilly‚Äôs fair value estimate has shifted from US$1,093.22 to US$1,211.21, capturing an updated view of what analysts are willing to pay for its long term earnings power. That move aligns with recent research that emphasizes obesity leadership, cardiometabolic breadth, and deals like Ventyx, while still highlighting valuation and execution risks. As you read on, you will see how these factors shape the evolving narrative and what to watch as new opinions emerge. Stay updated as the Fair...",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-narrative-shifting-231339328.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2fae4fd7-8d43-3457-b08f-a719ee732c81",
      "content": {
        "id": "2fae4fd7-8d43-3457-b08f-a719ee732c81",
        "contentType": "STORY",
        "title": "How The Eli Lilly (LLY) Narrative Is Shifting Around Obesity Leadership And Valuation Risks",
        "description": "",
        "summary": "Eli Lilly‚Äôs fair value estimate has shifted from US$1,093.22 to US$1,211.21, capturing an updated view of what analysts are willing to pay for its long term earnings power. That move aligns with recent research that emphasizes obesity leadership, cardiometabolic breadth, and deals like Ventyx, while still highlighting valuation and execution risks. As you read on, you will see how these factors shape the evolving narrative and what to watch as new opinions emerge. Stay updated as the Fair...",
        "pubDate": "2026-02-23T23:13:39Z",
        "displayTime": "2026-02-23T23:13:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-narrative-shifting-231339328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-narrative-shifting-231339328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T22:41:16+00:00",
    "headline": "Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short",
    "summary": "Today, Feb. 23, 2026, a pivotal obesity‚Äëdrug trial setback forces investors to rethink Novo Nordisk‚Äôs strategy.",
    "url": "https://www.fool.com/coverage/stock-market-today/2026/02/23/stock-market-today-feb-23-novo-nordisk-plunges-16-after-obesity-drug-falls-short/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "18acd46d-3fc7-316d-8eac-3cc2ed5b64d9",
      "content": {
        "id": "18acd46d-3fc7-316d-8eac-3cc2ed5b64d9",
        "contentType": "STORY",
        "title": "Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short",
        "description": "",
        "summary": "Today, Feb. 23, 2026, a pivotal obesity‚Äëdrug trial setback forces investors to rethink Novo Nordisk‚Äôs strategy.",
        "pubDate": "2026-02-23T22:41:16Z",
        "displayTime": "2026-02-23T22:41:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/a2f2374d3f08fab54d1bd5abe908bf3d",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rFSkEXfTutodclnu_KusZg--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a2f2374d3f08fab54d1bd5abe908bf3d.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NptAHEiEiBtdeSrE8d_rZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a2f2374d3f08fab54d1bd5abe908bf3d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/stock-market-today/2026/02/23/stock-market-today-feb-23-novo-nordisk-plunges-16-after-obesity-drug-falls-short/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-feb-23-224116326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T22:33:45+00:00",
    "headline": "Stocks to Watch Monday Recap: Diamondback, Netflix, Novo Nordisk, Lilly",
    "summary": "‚ÜòÔ∏è Hims & Hers Health (HIMS): The telehealth platform said it expects growth to continue this year, though its first quarter guidance came in short of Wall Street‚Äôs expectations. Shares slipped 2% afterhours.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday Recap: Diamondback, Netflix, Novo Nordisk, Lilly",
        "description": "",
        "summary": "‚ÜòÔ∏è Hims & Hers Health (HIMS): The telehealth platform said it expects growth to continue this year, though its first quarter guidance came in short of Wall Street‚Äôs expectations. Shares slipped 2% afterhours.",
        "pubDate": "2026-02-23T22:33:45Z",
        "displayTime": "2026-02-23T22:33:45Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-recap-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/fdd47d79dd303dd8ed75edc6302549ad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fE8MPZmAGd3rI2qE9tOdFg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/fdd47d79dd303dd8ed75edc6302549ad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.05UnUkL1bcbBSdeL6wDDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/fdd47d79dd303dd8ed75edc6302549ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "FBIN"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "FANG"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CL=F"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T22:31:55+00:00",
    "headline": "Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower",
    "summary": "AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.",
    "url": "https://www.fool.com/coverage/stock-market-today/2026/02/23/stock-market-today-feb-23-nvidia-earnings-loom-as-tariff-concerns-drive-dow-800-points-lower/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "88f60a5d-9768-328d-8f5a-568a230fa983",
      "content": {
        "id": "88f60a5d-9768-328d-8f5a-568a230fa983",
        "contentType": "STORY",
        "title": "Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower",
        "description": "",
        "summary": "AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.",
        "pubDate": "2026-02-23T22:31:55Z",
        "displayTime": "2026-02-23T22:31:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3fd91aefbc0f3ae77ac19e9b8ae72d86",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JhtKH2J5zAYw9PhxWGnHeg--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fd91aefbc0f3ae77ac19e9b8ae72d86.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5fNIDHkqDVYnT6CFBBxKnA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fd91aefbc0f3ae77ac19e9b8ae72d86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/stock-market-today/2026/02/23/stock-market-today-feb-23-nvidia-earnings-loom-as-tariff-concerns-drive-dow-800-points-lower/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-feb-23-223155981.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBM"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "ANTH.PVT"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T22:17:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Novo Nordisk, Eli Lilly, Gilead Sciences and more in the latest Market Talks covering Health Care.",
    "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-0c3d0d8a?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "3bce75c4-4b78-3982-897f-6cc92490faa2",
      "content": {
        "id": "3bce75c4-4b78-3982-897f-6cc92490faa2",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Novo Nordisk, Eli Lilly, Gilead Sciences and more in the latest Market Talks covering Health Care.",
        "pubDate": "2026-02-23T22:17:00Z",
        "displayTime": "2026-02-23T22:17:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3bce75c4-4b78-3982-897f-6cc92490faa2/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/cf424bcc23dd89e2ecb9a455fae7790a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/boe5DFFJdjfQK3lIHFKNpg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/cf424bcc23dd89e2ecb9a455fae7790a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/digV8uTrj_8vdBaYyi2clQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/cf424bcc23dd89e2ecb9a455fae7790a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-0c3d0d8a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:39:31+00:00",
    "headline": "Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?",
    "summary": "Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly‚Äôs competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.",
    "url": "https://www.barchart.com/story/news/373204/novo-nordisk-stock-is-deeply-oversold-on-weight-loss-drug-fail-should-you-buy-the-dip",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "5d6fa857-39ea-39c0-8f8e-e1f7047229ec",
      "content": {
        "id": "5d6fa857-39ea-39c0-8f8e-e1f7047229ec",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?",
        "description": "",
        "summary": "Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly‚Äôs competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.",
        "pubDate": "2026-02-23T21:39:31Z",
        "displayTime": "2026-02-23T21:39:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/735d268f447a913dbfe608b86b5b04eb",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "The Novo Nordisk logo on a corporate building by Kittyfly via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fXUJLKJV1lSBZcD9OwkKmQ--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/735d268f447a913dbfe608b86b5b04eb.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cOp2c3D2TTKfavhxoSgU0Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/735d268f447a913dbfe608b86b5b04eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/373204/novo-nordisk-stock-is-deeply-oversold-on-weight-loss-drug-fail-should-you-buy-the-dip",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-stock-deeply-oversold-213931046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T21:36:15+00:00",
    "headline": "Stocks Finish Sharply Lower on Trade Uncertainty and AI-Disruption Fears",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -1.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.21%. March E-mini S&P futures (ESH26 ) fell -1.02%, and March E-mini Nasdaq futures...",
    "url": "https://www.barchart.com/story/news/373073/stocks-finish-sharply-lower-on-trade-uncertainty-and-ai-disruption-fears",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "f1d71980-d7ad-30d9-a372-a030e5a699e4",
      "content": {
        "id": "f1d71980-d7ad-30d9-a372-a030e5a699e4",
        "contentType": "STORY",
        "title": "Stocks Finish Sharply Lower on Trade Uncertainty and AI-Disruption Fears",
        "description": "",
        "summary": "The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -1.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.21%. March E-mini S&P futures (ESH26 ) fell -1.02%, and March E-mini Nasdaq futures...",
        "pubDate": "2026-02-23T21:36:15Z",
        "displayTime": "2026-02-23T21:36:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/41d29dada4ef69b1b608c5d19cfef5d7",
          "originalWidth": 1600,
          "originalHeight": 1068,
          "caption": "Down day candlestick chart by Bigc Studio via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G0lXT5UShALCsC9RjDywRQ--~B/aD0xMDY4O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/41d29dada4ef69b1b608c5d19cfef5d7.cf.webp",
              "width": 1600,
              "height": 1068,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2bhhFAcylqoLtFMFRF1nAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/41d29dada4ef69b1b608c5d19cfef5d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/373073/stocks-finish-sharply-lower-on-trade-uncertainty-and-ai-disruption-fears",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-finish-sharply-lower-trade-213615079.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^NDX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]